Stocks
Rezolute, Inc.RZLT
NASDAQHealthcareBiotechnology$3.86
Price as of · delayed, not real-time
A clinical-stage biopharmaceutical company developing therapies for rare and metabolic diseases, with a lead candidate targeting congenital hyperinsulinism. Its pipeline also includes treatments for diabetic macular edema and other conditions. Investors track RZLT for its orphan drug programs and upcoming clinical trial readouts.
52W Range: $1.07-$11.46
Congressional Interest in Rezolute, Inc. (RZLT)
No congressional trades have been disclosed for Rezolute, Inc. (RZLT) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
0
Unique Politicians
0
Buys
0
Sells
0
Who in Congress Is Trading RZLT?
No congressional trades found for this stock.